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Abstract
Objective To perform planned subtotal resection followed by
gamma knife surgery (GKRS) in a series of patients with large
vestibular schwannoma (VS), aiming at an optimal functional
outcome for facial and cochlear nerves.
Methods Patient characteristics, surgical and dosimetric fea-
tures, and outcome were collected prospectively at the time of
treatment and during the follow-up.
Results A consecutive series of 32 patients was treated be-
tween July 2010 and June 2016. Mean follow-up after surgery
was 29 months (median 24, range 4–78). Mean presurgical
tumor volume was 12.5 cm3 (range 1.47–34.9). Postoperative
status showed normal facial nerve function (House–
Brackmann I) in all patients. In a subgroup of 17 patients with
serviceable hearing before surgery and in which cochlear
nerve preservation was attempted at surgery, 16 (94.1%)
retained serviceable hearing. Among them, 13 had normal
hearing (Gardner–Robertson class 1) before surgery, and 10
(76.9%) retained normal hearing after surgery. Mean duration
between surgery and GKRS was 6.3 months (range 3.8–13.9).
Mean tumor volume at GKRS was 3.5 cm3 (range 0.5–12.8),
corresponding to mean residual volume of 29.4% (range 6–
46.7) of the preoperative volume. Mean marginal dose was
12 Gy (range 11–12). Mean follow-up after GKRS was
24 months (range 3–60). Following GKRS, there were no
new neurological deficits, with facial and hearing functions
remaining identical to those after surgery in all patients.
Three patients presented with continuous growth after
GKRS, were considered failures, and benefited from the same
combined approach a second time.
Conclusion Our data suggest that large VSmanagement, with
planned subtotal resection followed by GKRS, might yield an
excellent clinical outcome, allowing the normal facial nerve
and a high level of cochlear nerve functions to be retained.
Our functional results with this approach in large VS are com-
parable with those obtained with GKRS alone in small- and
medium-sizedVS. Longer term follow-up is necessary to fully
evaluate this approach, especially regarding tumor control.
Keywords Combined approach . Vestibular schwannoma .
Surgery . Radiosurgery . Gamma knife
Introduction
The surgical management of benign skull-base tumors has
evolved greatly in the last few decades, primarily in
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connection with the advancement of modern microsurgical
techniques, which have significantly decreased the morbidity
associated with the resection of these tumors [17, 18, 64]. On
the other hand, several large series of radiosurgery for the
treatment of small and medium benign skull-base lesions have
demonstrated adequate long-term tumor control, along with
very low neurological morbidity and improved preservation
of functions, especially with regard to the risk for cranial nerve
deficit, compared with surgery [20, 39, 41, 59, 66]. In large
tumors, radical surgery alone yields a high risk for neurolog-
ical deficit, and radiosurgery cannot be used safely as a first
line of treatment because of the high risk for radiation-induced
complications associated with large-volume tumors.
For vestibular schwannoma (VS), postoperative facial
nerve and hearing dysfunction reported in the literature over
several large series with surgery remains significant [1, 9, 31,
62]. Gamma knife surgery (GKRS) allows for optimal func-
tional results in small and medium-sized VS, and has become
a valuable alternative to upfront management in those cases
[39, 41, 66]. Nowadays, patients with large VS have high
expectations regarding the functional outcome of surgery,
looking for results similar to those of patients treated with
GKRS for smaller tumors.
Here, we present our experience with large VS using a
treatment paradigm of a combined approach with microsur-
gery and GKRS, aiming to optimize the functional outcome
for the facial and cochlear nerves.
Materials and methods
Study design and patient population
The study was designed as an open and prospective study. A
case report form was generated prospectively for each patient
at treatment time.
Between July2010and June2016, a total of 257patientswith
VS (all grades included)were treated at the LausanneUniversity
Hospital, Switzerland.Whenever applicable,GKRSwasused as
the first-line treatment. Inclusion criteria for the combined ap-
proach were patients with Koos grade IV, who were not consid-
ered for upfront GKRS because of their size and/or significant
brainstem compression. Furthermore, it is known that Koos
grade IV tumors may vary significantly in tumor volume [42].
Therefore, the respective volumes are further detailed in Table 1
and in theResults sectionof thepresent paper (Demographic and
preoperative data). Exclusion criteria for the present study were
patients with VS treated with upfront GKRS during the same
period of time, and patients with type II neurofibromatosis who
benefitted from the combined approach.
In 32 patients (12.4%)withKoos grade IVwhomet the inclu-
sion criteria planned subtotal microsurgical resection was per-
formed within the framework of a combined approach. This
represents the total number of patients receiving open surgery for
VS of any size during the study period. Among the 32 cases, 3
patients treated primarily with GKRS continued to progress and
were considered asGKRS failures after 3years of follow-up; they
were operated on using the same combined approach, and were
therefore included in this study. Likewise, 1 patient previously
treatedelsewherewith fractionatedradiation therapy,and1patient
treatedwithLINACradiosurgery,werealsoconsideredasfailures,
were managed using the same combined approach, and were in-
cluded in this study.All the surgical resectionswereperformedby
the first author (RTD), and all GKRS were performed by the last
author (ML).
Table 1 Demographic and surgical data and clinical assessment
Patient
number
Sex Age
(years)
TVat
surgery
(cm3)
G-R
class
before
surgery
G-R
class
after
surgery
H–B
grade
before
surgery
H–B
grade
after
surgery
1 Male 61.2 16.1 5 5 I I
2 Female 66.4 24 5 5 I I
3 Female 34.4 11.3 1 1 I I
4 Male 48.3 9.7 5 5 I I
5 Male 44.2 10.4 3 3 I I
6 Male 73.4 14.9 5 3 I I
7 Male 69.9 27.4 5 5 I I
8 Female 51.2 16.3 5 5 I I
9 Male 34.4 34.9 5 5 I I
10 Female 64.2 15.7 5 5 I I
11 Female 32.5 25 1 5 I I
12 Female 52.2 7.7 1 1 I I
13 Female 48.3 19.9 1 1 I I
14 Female 57.5 9.3 1 3 I I
15 Male 73.8 10.1 5 3 I I
16 Female 51.2 12.7 5 5 I I
17 Female 46.2 5 3 3 I I
18 Female 44.2 13.5 1 1 I I
19 Female 34 13.5 5 5 I I
20 Female 54.2 1.5 1 1 I I
21 Male 66.7 7.9 4 4 I I
22 Male 50 15.3 1 1 I I
23 Female 51 7.4 3 2 I I
24 Female 33 6 1 1 I I
25 Male 55 15 5 5 I I
26 Female 72 3.6 5 5 I I
27 Female 41 3.2 1 1 I I
28 Male 36 14.3 1 1 I I
29 Female 40 3.6 3 2 I I
30 Male 45 8.8 1 1 I I
31 Female 39 5.2 1 3 I I
32 Male 85 9.3 4 5 IV I
TV tumor volume, G–R Gardner–Robertson, H–B House–Brackmann
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Follow-up included patients and tumor characteristics ana-
lyzed at baseline (before surgery) and at regular follow-up
intervals both after surgery and after GKRS; clinical assess-
ment and magnetic resonance imaging (MRI) were performed
after surgery and at 6, 12, 24, and 36 months after GKRS
(unless otherwise clinically indicated). Parameters included
age, symptoms at initial presentation, and the neurological
examination. The facial nerve function was classified using
the House–Brackmann (H–B) grading scale [26]. During the
follow-up period, it was always performed independently by
the second (CT, neurosurgeon) and third authors (MG, ENT),
who were not involved in the surgery.
Thehearingassessment includedpure toneaudiometry (PTA)
and speech discrimination score (SDS) and was graded accord-
ing to the Gardner–Robertson (G–R) classification scale [16].
Maximal diameter was defined as the largest diameter after
measuring all three axes (lateral, antero-posterior and supero-
inferior). The volume was defined by automatic segmentation
using Leksell GammaPlan® planning software (Elekta
Instruments AB, Stockholm, Sweden) on all MR data, includ-
ing the preoperative images. The tumor size (maximal diam-
eter) and volume were measured on the serial MRI [35].
Surgical technique
All patientswere operated onusing the retrosigmoid approach in
the lateral decubitus position, as previously described by several
authors [5,7,8,11,62]. Intraoperativeneuromonitoring (IOM) is
anessentialpartof this surgery.The twomaingoalsof IOMare to
precisely define the anatomical location of the nerves in the
cerebellopontine angle and to preserve the functional integrity
of the facial and cochlear nerves. Bipolar electrodes are placed
in the frontalis, orbicularis occuli, orbicularis oris, and mentalis
muscles. Glossopharyngeal and vagus nerves are monitored
using contact electrodes incorporated in the endotracheal tube
(Xomed®; Medtronic, Jacksonville, FL, USA). Electrodes
inserted into the trapezius muscle are used for monitoring the
eleventh nerve function using an NIM-Eclipse® (Medtronic)
intraoperative monitoring system with free-running electromy-
ography(EMG)andcompoundmuscleactionpotential (CMAP)
after direct nerve stimulation using monopolar 1-Hz,
monophasic negative 200-μs duration electrical stimulation.
Alert criteria are a stimulation response at low stimulation inten-
sity indicating nerve proximity or spontaneous EMGbursts last-
ing more than 30 s on the free-running EMG. In patients with
preserved hearing, brainstem auditory evoked responses
(BAER) are used to monitor the integrity of the cochlear nerve.
The durotomy is performed in a linear fashion 5–8 mm
from the border of the sigmoid sinus and the transverse sig-
moid junction. The lateral cerebellomedullary cistern is
opened to let out the CSF and relax the cerebellum. The tumor
is then visualized in the cerebellopontine angle. The posterior
capsule of the tumor is stimulated to look for an aberrant facial
nerve course, after which the posterior capsule is opened.
Tumor decompression is performed with an ultrasonic aspira-
tor and the tumor capsule progressively mobilized from the
cerebellum and brainstem. The microsurgical strategy for a
planned subtotal resection differs from that for a maximized
or total excision in several aspects. When a total excision is
planned for, the plane between the tumor and the facial nerve
is identified by visual and electrophysiological means. This
plane is then followed from the root entry zone to the internal
auditory meatus (IAM) to remove the capsule (after adequate
internal decompression) in its entirety. The arachnoidal rela-
tionships of the facial and cochlear nerves with the tumor
capsule is a matter of debate and possibly depends on the
whether the tumor is of an epi- or subarachnoid origin. In
the author’s earlier experience with total excisions of large
VS, it was very difficult, if not impossible, to identify arach-
noid between the tumor capsule and the facial and cochlear
nerves and all these structures are contained within a single
cistern. The damage to these nerves is very likely to be due to
a combination of the manipulation of extremely thinned out
nerves and compromise of the vascular supply to these nerves.
The present strategy (in this series) of a planned subtotal tu-
mor excision takes advantage of the fact that this plane is not
entered into and thus obviating these factors that lead to neural
compromise. The thinned out capsule of the tumor is progres-
sively excised till the superior and inferior border of the facial
nerves are identified by IOM. This is performed by stimula-
tion of the external part of the capsule with a current smaller
than 1 mA. This current is progressively decreased till the
smallest current that evokes a positive response is identified.
This parameter is then used as a standard during the entire
procedure, whenever the external capsule is stimulated. The
tumor capsule covering the facial nerve is stimulated from
within the tumor at currents of 4–5 mA and progressively
the current is decreased till 2 mA. In our experience, if a
positive stimulation is achieved internally at 2 mA, the thick-
ness of the residual capsule is around 2–3 mm. The capsule is
also turned and inspected (and stimulated) from its external
surface to estimate the thickness (Fig. 1a, b). The free-running
EMG responses are used during surgery for alert criteria as
described above. Combining electrophysiological responses
with visual inspection gives the best chance of achieving a
uniformly Bsmall^ thickness residual capsule that protects
the facial nerve course from surgical damage. At the end of
surgery, facial nerve integrity is tested using direct brainstem
stimulation at the level of the facial root entry zone, and in our
series, facial nerve response could be elicited by stimulation
less than 1 mA in all patients. In addition, there was no per-
sistent EMG-bursting activity at the end of surgery, indicating
the absence of an axonal lesion of the facial nerve. The open-
ing of the internal auditory meatus (IAM) is not part of our
strategy within the framework of this combined approach; the
IAM is not opened because this is the region where the nerves
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are most vulnerable. The only exception was for one case,
where the patient presented with a progressive facial nerve
paresis preoperatively, due to a large multilobulated tumor
component within the meatus. The decompression of the tu-
mor within the meatus allowed for complete facial nerve re-
covery (H–B grade IV improved to grade I).
Cochlear nerve preservation is more difficult to achieve, as
there are no stimulation methods that allow clear electrophys-
iological identification of the cochlear nerve for large tumors.
BAER is used in a continuous manner with defined alert
criteria such as reduction of peak III amplitude of more than
50%. The identification of the facial nerve course from the
internal auditory meatus to the root entry zone at the brainstem
allows for prediction of the course of the cochlear nerve,
which is presumably located caudally (inferiorly) to the facial
nerve. The thickness of the residual capsule over the cochlear
nerve is kept to a similar degree as that achievedwith the facial
nerve, guided by a visual assessment.
Early postoperative MRI is performed as a baseline for
evaluating the volume and shape of the residual tumor, and
GKRS is planned a few months later, after a new MRI has
been performed, expecting that the residual capsule has closed
on itself gradually, owing to brain pulsations and reduction of
the mass effect (Fig. 1c, d).
Gamma knife radiosurgery technique
The Leksell G stereotactic frame (Elekta instruments AB,
Stockholm, Sweden) was fixed under local anesthesia and
mild sedation, with specific attention given to avoiding the
area of the previous posterior fossa craniotomy. All patients
underwent stereotactic MRI (1.5 Tesla, Siemens, Erlangen,
Germany) and computed tomography (CT) with bone win-
dows. The MR sequences used are T1-weighted with and
without gadolinium contrast medium and T2 CISS, without
contrast medium (in small remnants) and/or with contrast me-
dium (in larger remnants); T2 CISS with contrast medium
helps to differentiate between the nerves and the tumor [24].
Target definition and treatment dosimetry were performed
using Leksell GammaPlan® planning software version 10 or
11. The modiolus of the cochlea was defined on bone CT
images and the dose received was further calculated (as the
dose received by the first 1% of the volume, and as the max-
imum dose). If this dose was more than 4 Gy in patients with
useful hearing, additional sector blocking was used to ensure
that optimal dosimetry results are obtained, as we routinely
perform in patients undergoing upfront GKRS for smaller
tumors [41, 60]. The stereotactic irradiation was delivered
using the Leksell Gamma Knife® Perfexion™ (Elekta
Fig. 1 Schematic representation of a planned subtotal resection and
gamma knife surgery (GKRS) planning of large vestibular schwannoma
(VS). Upper part: illustrations of a the tumor in the coronal plane
surrounded by the nerves that enter the internal auditory canal, and its
relationship to the brainstem, b the internal decompression of the tumor
guided by stimulation of the nerve, both from the external side of the
capsule and through the residual capsule, c the progressive closure of
the residual capsule and relief of brainstem compression, d the final size
and shape of the residual tumor for GKRS. Lower part: e preoperative
MRI, f intraoperative view, g immediate postoperative MRI (24 h after
surgery), and hMRI at the time of GKRSwith the dosimetry (prescription
isodose volume colored in yellow, and the 4-Gy isodose line in green,
while the cochlea is colored in magenta)
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Instruments AB, Stockholm, Sweden). The procedure was
performed on an ambulatory basis.
Data analysis
All collected data were analyzed for the whole group (32 pa-
tients). Moreover, data were analyzed separately in the sub-
group of patients with serviceable hearing before surgery and
inwhichpreservationof cochlearnerve functionwas attempted
(group A, G–R 1–3, n = 17), and in patients with no residual
preoperative hearing (group B, G–R 4 and 5, n = 15).
Statistical analysis
All statistical analyses were conducted using Stata (STATA
version 11 (STATA, College Station, TX, USA) and
GraphPad Prism software 5.02. For tumor control after
GKRS, survival over time was examined using the Kaplan–
Meier method. Patients censoring occurred at the moment of
failure (for the 3 cases who needed a second combined ap-
proach), or at last follow-up otherwise (for stability or de-
crease in size during follow-up course respectively). For the
two-sample t test (continuous variables), a p value of <0.05
was considered statistically significant. For categorical vari-
ables, Chi-squared test was performed. Owing to insufficient
sample size no multivariate analysis was carried out.
Results
Demographic and preoperative data
Thirty-two patients (13 male and 19 female) with large VS
have undergone planned partial microsurgical resection with
this approach, followed by GKRS. The mean age at the time
of surgery was 51.7 years (range 32.5–85).
The clinical presentation was progressive hearing loss (20
cases,62.5%),suddenhearingloss(2cases,6.25%),gaitproblems
(2 patients, 6.25%), trigeminal nerve symptoms (2 cases, 6.25%),
tinnitus (1 case, 3.12%), vertigo (4 cases, 12.5%), and was an
incidental finding in 1 case (3.12%).TheVSwas solid in29 cases
(90.6%), andmixed (solid and cystic) in 3 patients (9.7%).
All patients had normal facial nerve function (H–B I) be-
fore surgery, except for one patient who was had H–B IV
before surgery. All patients underwent preoperative hearing
evaluation consisting of tonal and vocal audiometry. Hearing
status according to the G–R scale is displayed in the Table 1.
The mean presurgical tumor volume was 12.5 cm3 (range
1.47–34.9) and the mean presurgical maximal diameter was
33.2 mm (median 35, range 20–45). The mean tumor volume
was 9.8 cm3 (range 1.47–25) in group A, and 15.4 cm3 (range
3.6–34.9) in group B (p = 0.03, two sample t test). The mean
maximal diameters in groups A and B were 30.6 (median 30,
range 20–42) and 36.1 (median 37.7, range 26–45) respective-
ly (p = 0.01, two sample t test).
Postoperative data and functional outcome
The mean follow-up after surgery was 29 months (median 24,
range 4–78). One patient was lost to follow-up owing to relo-
cation to another country.
Postoperative clinical status showed normal facial nerve
function (H–B I) in all operated patients (i.e., 100% preserva-
tion of normal facial nerve function, including the recovery of
the facial function of the patient who presented with H–B IV
preoperatively).
Cochlear nerve preservation surgery was attempted for the
17 patients in group A who presented with G–R class 1 (13
patients) or G–R 3 (4 patients) before surgery. Of the 13 pa-
tients in G–R class 1, postoperative audiogram showed that 10
(76.9%) remained in G–R class 1, two were in G–R class 3
(15.4%), and one (7.7%) lost hearing (G–R class 5). Of the 4
patients in G–R class 3, postoperative audiogram showed that
2 remained in the same class after surgery, and that PTA im-
proved in 2 of them during follow-up (G–R class 2). In sum-
mary, postoperative hearing status in group Awas identical or
better in 14 out of 17 patients (82.3%) and useful postopera-
tive hearing (G–R 1) in this group was maintained in 10 out of
13 patients (76.9%).
In group B, i.e., the 15 patients with no serviceable hearing
before surgery (G–R 4 and G–R 5), of the 13 patients present-
ing with G–R 5, two improved to G–R 3 after surgery; from
the two patients in G–R 4 preoperatively, one remained in the
same hearing class and one passed to G–R 5 after surgery.
The mean PTAvalues for patients with serviceable hearing
before surgery were 37.2 dB (median 40, range 5–80) and
after surgery they were 46.4 (median 45, range 5–120;
p = 0.3, two sample t test). At 6 months after GKRS, the mean
value was 49.6 (median 45, range 105–120; p = 0.55, two
sample t test, compared with the values immediately after
surgery). At 12 months after GKRS the mean values were
61.7 (median 66.2, range 15–120; p = 0.35, two sample t test,
compared with 6 months after GKRS) and at 24 months they
were 62.7 (median 70, range 8.7–120; p = 0.96, two sample t
test, compared with 12 months after GKRS; p = 0.42, two-
sample t test, compared with baseline, before GKRS). Of note,
as the follow-up period is still short in some cases, the number
of observations before surgery, after surgery, and at 6 months
after GKRS was 15 and dropped to 8 at 1 year, to 5 at 2 years,
and to 2 at 3 years after GKRS.
One of the 2 patients, who presented with secondary tri-
geminal neuralgia before surgery, had transient facial
hypoesthesia following surgery. Trigeminal neuralgia disap-
peared in both cases. One patient had a transient vagus nerve
deficit, with full recovery after 6 months. No other neurolog-
ical deficits were encountered after surgery.
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Gamma knife radiosurgery data and outcome
Although GKRS was generally planned to take place at
around 6 months after surgery, the exact timing depended on
the suitability of the target for GKRS and on the shape of the
residual tumor capsule on follow-up MRI. One expects that
the open residual capsule at the end of surgery gradually
closes on itself owing to brain pulsations and reduction of
the mass effect; ideally, a complete closure, therefore, converts
a large debulked VS into a small, more globular tumor with a
shape and size that become more suitable for GKRS (Fig. 2).
Most patients had early (within 48 h) postoperative MRI, and
all patients underwent MRI 3–4 months after surgery.
Depending on the size and shape of the residual tumor at that
time, GKRS was scheduled, or patients were further followed
with MRI. Three patients needed staged surgery (i.e., they
were operated on twice) before GKRS, because the residual
volume after the first surgery was still considered too large for
safe GKRS.
All 32 patients have undergone GKRS after surgery. The
mean duration between surgery and GKRS was 6.3 months
(median 6, range 3.8–13.9 months). The mean tumor volume
at the time of GKRS was 3.5 cm3 (range 0.5–12.8); this
corresponded to a mean residual volume of 29.4% (range 6–
46.7) of the preoperative volume (Table 2).
The volume at the time of GKRS, when compared with the
presurgical volume,wasbiggerwhencochlear nervepreservation
was attempted (groupA, 33.4%of pre-surgical volume; groupB,
25.1% of pre-surgical volume), as exemplified in Figs. 3 and 4.
Althoughtheseresultsdidnotreachstatisticalsignificance,despite
showingastrongtendency(p=0.059, twosample t test), therewas
a trend toward the tumors inGroupAbeing smaller and the tumor
remnant after GKRS to be larger in this group. This is essentially
related to thefact thata larger tumorcapsuleneeds tobe leftbehind
to preserve cochlear nerve function.
Themeanprescription isodosevolumewas4 cm3 (range0.6–
13.4). Themean number of isocenterswas 20 (median 20, range
7–33) and the meanmarginal prescription dose was 12 Gy (me-
dian 12, range 11–12 Gy); there was no dose reduction for pa-
tients with previous GKRS or other forms of radiation.
Themean conformity index for the combined serieswas 0.98
(range 0.92–1.00), the mean selectivity index was 0.81 (range
0.66–0.99), and themeangradient indexwas2.7 (range2.4–3.0).
Out of the 32 treated patients, 20 had at least 1 year of
follow-up post-GKRS. The global mean follow-up after
GKRS was 24 months (median 24 months, range 3–60).
Following GKRS, no new neurological deficits were encoun-
tered and hearing remained stable in all patients with pre-
served hearing post-surgery.
Tumor control after combined approach
Three patients (9.4%) had continuous growth of the VS after
the combined approach, with clinical worsening (see below),
and have been considered as failures, at 2.6, 2, and 1.25 years
after GKRS respectively. Thus, the actuarial local tumor con-
trol rate (LTC) at 1 year is 94%, at 2 years 88%, and at
2.6 years became 77% and further remained stable over time.
The three cases that were considered to be failures have
undergone a new combined approach. The first case (patient
#3 in the series, Fig. 5) was considered a failure 2 years after
the first GKRS. She presented with intractable, recurrent sec-
ondary trigeminal neuralgia and a new MRI showed a contin-
uous increase in tumor volume. She has been further re-
operated 2 years after the first GKRS. She retained hearing
(G–R class 1) at 2 years after the second GKRS, and facial
nerve function remained normal (H–B I). The second case
(patient #9 in the series) was considered a failure 2.6 years
after GKRS. He presented with recurrent gait instability, and
the new MRI displayed a significant increase in tumor
Fig. 2 Representative axial images of T1-weighted contrast-enhanced
MRI showing the preoperative size of the tumor (left), the residual capsule
immediately after surgery (center), and the folding of the capsule and
reduction of mass effect on the brainstem at the time of GKRS (right),
which results in a compact and small target volume
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volume. He has been further reoperated 2.6 years after the first
GKRS. He already had no residual hearing before the first
combined approach. Facial nerve function was normal (H–B
I) after the 2nd surgery. The third case (patient #11 in the
series) was considered a failure 1.25 years after GKRS. She
presented with intractable headaches and serial MRI controls
that displayed a continuous major increase in tumor volume.
She was further reoperated 1.25 years after GKRS. She had
already lost hearing after the first combined approach, and
facial nerve function remained normal (H–B I) after the new
surgery.
The ages of these patients were 34.4, 34.4, and
35.2 years (mean 34.6) respectively, i.e., among the
youngest patients in our series. The volumes at the time
of GKRS were 4, 7.7, and 6.6 cm3 respectively. Review
of the pathological condition did not show any change in
the histopathological grade between the two surgeries, and
there were no signs of malignant transformation.
The distinction between TTE and tumor growth is not al-
ways easy. In our cases, the clinical condition and symptoms,
in addition to the continuous growth onMRI, were in favor of
treatment failure, and we decided to perform a new combined
approach in these patients. As illustrated in the literature, the
decision whether to continue to wait-and-scan or to act by a
new therapeutic means is always a clinical decision, and
Bnever just a matter of volume measurements^ [43, 47, 58].
Table 2 Gamma knife
radiosurgery dosimetric data Patient
number
TV at GKS
(cm3)
Percentage of
residual tumor
PIV at GKS
(cm3)
Prescribed dose
(Gy; at the 50%
isodose line)
1 0.963 6 1.38 12
2 2.4 10 3.01 12
3 4 35.4 4.75 12
4 3.2 33 3.48 11
5 3.3 31.7 3.83 11
6 0.537 3.6 0.792 12
7 7.6 27.7 8.87 12
8 6.6 40.5 7.56 12
9 12.8 36.7 13.41 12
10 7.05 44.9 7.59 12
11 7.7 30.8 7.8 12
12 3.6 46.7 4.15 12
13 4 20.3 4.54 12
14 3.38 36.3 3.69 12
15 1.62 16 1.94 12
16 4.04 31.8 4.5 12
17 1.38 27.6 1.68 12
18 2.5 18.5 3.34 12
19 2.42 17.9 2.92 12
20 0.519 35.3 0.665 12
21 1.44 18.3 1.91 12
22 3.62 23.6 4.23 12
23 2.17 29.4 2.99 12
24 1.24 20.8 1.6 12
25 4.74 31.6 5.6 12
26 1.29 35.4 1.64 12
27 1.5 46.6 1.58 12
28 5.51 41.9 7.01 12
29 0.721 20.3 0.981 12
30 5.57 63.2 6.54 12
31 2.12 40 2.57 12
32 1.9 20.5 2.482 12
PIV prescription isodose volume
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Discussion
The optimal management of VS remains a matter of debate.
For small to medium-sized lesions, the options are radiosur-
gery, microsurgery or a Bwait and scan^ approach. Small to
medium-sized (Koos grade I to III) symptomatic lesions can
be treated either by surgery or by radiosurgery based on sur-
geon preference or availability of expertise. For small to
medium-sized tumors, comparative studies suggest that
GKRS might compare favorably with microsurgery, with a
high degree of local tumor control, a much lower rate of facial
nerve palsy, and a much higher rate of serviceable hearing
preservation [44, 46, 51, 52, 55]. Recent clinical trials have
suggested pro-active radiosurgical treatment, even in small
Koos grade I intracanalicular tumors [57].
Large symptomatic VS are generally considered to be an indi-
cation for microsurgical excision, except in cases with significant
co-morbidities contraindicating open surgery. The management
remains challenging, especially with regard to facial and cochlear
nerveoutcomes.TheexpectationsofthepatientswithlargeVSand
their referral doctors have increased, especially in the current con-
text of high-quality outcomes that are available for patients with
smaller lesions treated with GKRS. Thus, patients with large VS
areoften referred to centers equippedwith radiosurgery, expecting
results comparable with those reported in patients with smaller
lesions. The change in our treatment paradigm for the treatment
of largeVSwasmade specifically to address those issues.
In our series, only 32 out of 257 patients (12.4%) had Koos
grade IV tumors,whichmay seem a comparably lowpercentage
compared with other studies. However, if we look at recent
Fig. 3 Illustrative case in group
A (cochlear nerve preservation
attempt at surgery). A 39-year-old
female patient presented with
minimal loss of hearing
(Gardner–Robertson class 1) be-
fore surgery. The T1-weighted
axial contrast-enhanced MRI
showed a large VS, with a preop-
erative tumor volume of 5.23 cm3
(left). The tumor volume was re-
duced to 2.12 cm3 (i.e., 40% of
the preoperative volume) at the
time of GKRS. The patient
remained in Gardner–Robertson 1
after surgery and had normal fa-
cial nerve function (House–
Brackmann I)
Fig. 4 Illustrative case in group
B (no attempt at cochlear nerve
preservation at surgery). A 67-
year-old woman presented with
loss of hearing (Gardner–
Robertson class 5) and gait prob-
lems. The T1-weighted gadolini-
um-enhanced MR axial images
showed very large VS with sig-
nificant brainstem compression,
with a preoperative tumor volume
of 24 cm3. The tumor volumewas
reduced to 2.4 cm3 (i.e., 10% of
the preoperative volume) at the
time of GKRS. The facial nerve
function remained normal
(House–Brackmann I)
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studies with approaches comparable with ours, we may find an
even lowerpercentageofKoosgrade IV tumors. For example, in
Iwaiet al. [29],which isa large serieswitha long-termfollow-up,
the percentage of Koos grade IV tumors is 10.5%. Thus, we
believe that it will be less and less uncommon to have a low
percentage of Koos grade IV tumors in modern series of VS,
especially in teamsoffering radiosurgery inaddition tocombined
approaches.
Facial nerve outcome in the management of large VS
For microsurgery of large VS, it has been well accepted that the
sizeofthetumoris themainpredictorforpreservationofthefacial
nerve, both anatomically and functionally [31, 64]. The risk for
facial nervedysfunction inpatientswithVS larger than3cmis6-
fold greater than in patients with smaller tumors [73]. In Samii
et al.’s seriesof largeVS[64], even thougha facialnerve function
considered excellent/goodwas achieved in 75%, subgroup anal-
ysis shows that only 25% of patients retained H–B I facial nerve
function after surgery. Following totalmicrosurgical resectionof
large VS (larger than 3 cm in size), facial nerve function
preservation (H–B I or II) was achieved in 27–58% [3, 31, 40,
62, 63, 79] in the major reported series.
A meta-analysis published by Gurgel et al. [21] analyzed
facial nerve outcomes after surgery for large VS depending on
the type of surgical excision. They found that H–B I or II were
reported in 65.2% of the 601 retrosigmoid approaches includ-
ed in their study. Furthermore, facial nerve outcomes were not
significantly different using translabyrinthine or retrosigmoid
approaches, but showed statistically better outcome, com-
pared with the extended translabyrinthine approach. In the
same meta-analysis [21], the authors found a strong and sig-
nificant association between the degree of resection and out-
come. Of the 80 patients with subtotal resection, 92.5% had
good facial nerve outcomes, compared with 74.6% and 47.3%
of those who received near-total resection and gross total re-
section respectively.
Subtotal resection achieves better preservation rates, be-
tween 82 and 88% (H–B I and II) [37, 50], and even almost
100% in some reports [27]. When using a combination of
microsurgery and radiosurgery for large VS, authors reported
facial nerve function preservation (H–B I and II) ranging be-
tween 85.7 to 95% [15, 27, 49, 50, 69]. For example, in the
Fig. 5 Illustrative case of a failure after a combined approach, which was
re-treated using the same approach. A 37-year-old woman presented with
minimal hearing loss (Gardner–Robertson class 1) and secondary intrac-
table trigeminal neuralgia. T1-weighted gadolinium-enhanced MR axial
images showed a large VS with significant brainstem compression that
had a preoperative tumor volume of 11.3 cm3 (upper image left); the
tumor volume was reduced to 4 cm3 following the surgery and at the time
of the first GKRS (upper image right); the trigeminal neuralgia disap-
peared and the patient retained functional hearing (Gardner–Robertson
class 1). The tumor continued to grow and at 2 years after GKRS, the
patient developed recurrent trigeminal neuralgia and gait instability; the
MRI showed that the tumor volume had continued to increase to 6.9 cm3
(lower left) and a second surgical resection was decided upon. The tumor
volume was reduced to 2.5 cm3 following the second surgery and at the
time of the second GKRS (lower right). She remains asymptomatic, with
normal facial nerve (House–Brackmann I) and hearing function
(Gardner–Robertson 1) following the two surgeries and the two GKRS
procedures
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series by Van de Langenberg et al. [69], after planned subtotal
resection, good facial nerve outcomes (H–B I or II) were re-
ported in 94% of the cases after microsurgery and GKRS. In
another series by Pan et al. [49], outcomes were reported after
intracapsular decompression (group I) or radical extracapsular
resection (group II). For group I, the pre- and post-surgical
tumor volumes were 17.5 ± 1.1 cm3 and 9.35 ± 1.02 cm3
respectively, and for the group II they were 16.4 ± 0.95 cm3
and 1.1 ± 0.14 cm3 respectively. For group I, 90% of the
patients retained excellent facial function (H–B I or II). For
group II, only 35% retained excellent facial nerve function
(data statistically significant).
It is worth noting that most of the series reporting facial
nerve function after microsurgical resection, Bexcellent^ or
Bgood^ results usually include patients in H–B I or II (or
sometimes reaching H–B I to III), which from the functional
point of view and quality of life of the patients is not similar to
Bnormal^ facial nerve function (i.e., H–B I).
For small- to medium-sized VS (Koos grades I to III) treat-
ed with first-line GKRS, Regis et al. [60] recently reported
their experience in a very large cohort of 3,050 patients, with
2,336 having a minimum of 3 years’ follow-up, over a 20-year
period of experience. Although the global rate of transient
facial palsy was less than 0.5% in the entire series, there was
a definite trend in improved facial nerve outcomes with expe-
rience and new technology. Since the introduction of GKRS
robotization, facial nerve paresis has virtually disappeared in
their series. This observation is in agreement with our experi-
ence in treating VSwith GKRS, since the introduction and use
of the Leksell Gamma Knife® Perfexion™ in Lausanne, with
no permanent facial nerve impairment in our whole series.
Thus, our current results in patients with large VS, with
100% facial nerve functional preservation, H–B I outcome,
and a high level of hearing preservation, compete favorably
with the existing literature on the surgical management of
large VS. This supports the assumption that our combined
approach warrants strong consideration and further evaluation
as a preferred option for those patients with larger tumors.
Hearing outcome in the management of large VS
ThesizeofVSdoesnotnecessarily correlatewith thepresenceof
serviceablehearingat the timeofpresentation [68].Large tumors
can also present with good hearing levels. Hearing preservation
rates followingmicrosurgical resection in largeVSvarybetween
0 and 29% [12–14, 25, 63, 64, 73]. In one of the publications by
Samiiet al. [64], theprobabilityofhearingpreservationafter total
excision was estimated to be 11%. In a surgical series of 54
patients (75.9% total removal)withpreservedhearing at the time
of surgery and VS measuring ≥ 20 mm in extrameatal diameter
(16patientswith≥30mm), hearingpreservationwas achieved in
53.7%,butonly31%hadmaintenance(or improvement)ofhear-
ingat the same level asbefore surgery [71]. In a recent systematic
review on VS surgery, Ansari et al. [2] reported on 127 patients
with tumors with a maximal diameter larger than 3 cm. This
report did not provide the stratified data on the extent of tumor
removal across the series. Nevertheless, hearing preservation
was found to be possible in only 28.3% [2].DiMaio et al. report-
ed on a series of 46 large tumors (≥ 30 mm); 28 patients had
hearing preservation surgery and of these patients, 6 (21.4%)
had hearing preservation after surgery [10].
By comparison, for small to medium-sized tumors, radio-
surgery data show a hearing preservation rate ranging between
38% and 94% [6, 23, 34, 36, 38, 48, 56, 70, 74]. A recent
meta-analysis of published literature on GKRS for VS includ-
ed 28 studies published between 2007 and 2011, with 3,233
patients [61]. The average prescription dose was 12.4 Gy. The
preservation of serviceable hearing was on average 66.45%,
with a mean follow-up of 51 months. The authors also made a
comparison with similar studies [45, 72, 75–78], showing the
preservation of serviceable hearing in 20–57% of the patients.
In a systematic review, Yang et al. [77] included 45 articles,
with 4,234 treated patients, and a median reported follow-up
of 35 months. The mean GKRS dose was 14.2 ± 2.4 Gy. The
overall hearing preservation rate was 51%, irrespective of ra-
diation dose, tumor size or patient’s age. The authors conclud-
ed after a more detailed analysis that a marginal dose less than
13 Gy was associated with a higher rate of preserved hearing.
Recent literature reveals better hearing outcomes with the
subtotal excision of large VS, with or without additional ra-
diosurgery. Van de Langenberg et al. [69] reported hearing
preservation in only one of 4 patients with serviceable
presurgical hearing. In another series of 11 patients who
underwent intracapsular decompression of VS followed by
GKRS, Pan et al. [49] reported hearing to be preserved in all
patients, even though surprisingly, they reported only 89%
facial nerve preservation in the same series.
The results of our series are also in line with these reports,
showing hearing preservation that is comparable with those
results, or even better.
Tumor control
Vestibular schwannomas are known to have a small annual
rate of growth [65]. Despite this, recurrences may occur be-
tween 7 and 11% when surgical resection is considered to be
total [40, 62], and between 7 and 53% in subtotal resection
[19, 32, 33, 54]. There is a clear relationship between the
residual tumor volume and further recurrence. This observa-
tion is further confirmed by a recent series by Vakilian et al.
[67], in which the authors found that all VSwith a postsurgical
volume greater than 2.5 cm3 recurred.
Tumor control rates of GKRS in VS are reported to be as
high as 97.5% of the cases, with a median decrease in size of
40% at 7 years’ follow-up [60]. A recent meta-analysis of
published literature on GKRS for VS, which included 28
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studies published between 2007 and 2011 and 3,233 patients
reported an average tumor control of 92.7%, after a mean
follow-up of 51.24 months [61]. The authors also made a
comparison with similar studies [45, 72, 75–78], showing
81–100% tumor control for tumors ranging from 2.7 to 4 cm3.
The reported tumor control rate for combined approaches
ranges between 79% and 100%, with our study reporting
91.6% (Table 3). In this sense, our local control is perfectly
comparable with what has been published to date.
Nevertheless, an analysis of actuarial tumor control rates
would show lower rates (i.e., 90.7%, and actuarial rates of
94% at 1 year, 88% at 2 years, and 77% at 2.6 years, which
further remained stable over time) than in large series of up-
front GKRS for VS. However, at this stage of our analysis, the
interpretation of the actuarial control rate for the current
follow-up period, on a small sample size and a small number
of failures (only 3 cases) should be cautiously interpreted. As
there was no selection bias regarding the inclusion of patients
treated with our combined approach, several other hypotheses
may account for this finding. These large tumors could be
biologically more aggressive, a fact that cannot yet be proven
with standard neuropathological examinations. Although not
performed systematically in our series, many pathological
samples have been tested for Ki-67 or MIB1 indexes, and
did not show any abnormal increase in cell proliferation with
these markers (data not shown). Advances in pathological
evaluation, searching for specific biological markers for the
possible aggressive nature of VS, may help to better under-
stand the specific situation of these failures. Another impor-
tant factor could be the learning curve of the neurosurgical
technique, from the point of view of the ability to have the
thinnest and uniform residual capsule that is left in place cov-
ering the facial and cochlear nerves; the learning curve for the
GKRS planning in its ability to achieve an optimal plan in
these difficultly shaped target volumes could also be a factor
of failure. Of note, the 3 cases of failures happened in patients
treated early in this series (i.e., patients numbers 3, 9, and 11).
Increased experience with subtotal excision and optimized
planning radiosurgical strategies could reduce the incidence
of treatment failures with this approach.
Combination of surgery and GKRS for large VS
Surgery for large VS is currently considered the gold standard.
The number of patients presenting with large VS is decreas-
ing, as imaging diagnosis and management are performed
earlier in smaller tumors. For example, in our series, when
all consecutive patients managed in our center were consid-
ered, only 25 patients out of 217 (11.5%) presented with VS
too large for upfront GKRS, and underwent planned subtotal
surgical excision as part of a combined approach. This low
number reflects the incidence of large VS in a skull-base neu-
rosurgical center rather than low recruitment, as almost 90%
of our patients could be treated with upfront radiosurgery, and
VS represent more than 25% of our GKRS activity.
Although it seems that planned partial resection followed
by radiosurgery has become an increasingly popular approach
in the neurosurgical community, very few centers have report-
ed their results, as recently reviewed by Iwai et al. [28]. Pan
et al. [49] compared two groups of patients with large VS,
namely partial excision followed by GKRS (group 1 with 18
patients) versus total excision (group 2 with 17 patients). An
excellent facial nerve outcome (H–B I or II) was achieved in
89% in group I and in 35% in group II; hearing preservation
was 100% in group I and 0% in group 2. In Van de
Langenberg’s series of 50 patients with the same surgical strat-
egy [69], an excellent facial nerve outcome (H–B I or II) was
achieved in 94% and hearing was preserved in 1 out of 4
patients. A recent systematic review by Brokinkel et al. [4]
analyzed 6 studies of GKRS following subtotal resection.
There were 159 patients with a tumor diameter more than
2 cm. After a mean follow-up of 15 months, good facial nerve
function (H–B I or II) was achieved in 94%, whereas service-
able hearing preservation was achieved in 11.6%. Tumor
Table 3 Summary of the main series published in the literature
Reference Number of
patients
Follow-up
(months)
Facial nerve
preservation (%)
Cochlear nerve
preservation (%)
Tumor control
(%)
Iwai et al. [27] 14 32 85.7 NA 79
Park et al. [50] 8 68.8 NA NA 100
Yang et al. [78] 61 53.7 95 NA 93.5
Fuentes et al. [15] 8 46 87.5 NA 100
Van de Langenberg et al. [69] 50 33.8 94 25 (1/4) 90
Pan et al. [49] 18 57 89 100 (11/11) 100
Iwai et al. [28] 40 66 95 42.9 (6/14) 90
Radwan et al. [53] 22 28 87 NA 100
Present study 32 29 100 76.9 (10/13) 91.6
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growth control was achieved in 93.8%. Recently, Radwan
et al. [53] have presented their results in a series of 22 patients
treated with planned subtotal resection. Seventeen of them had
radiosurgery and 5 wanted to undergo a Bwait-and-scan^ strat-
egy for the remnant. Immediately after surgery, 68% of the
patients had good and moderate facial nerve function; howev-
er, 32% had significant facial weakness (H–B IV or even
higher). After a mean postoperative follow-up period of
28 months, 86.4% presented excellent facial nerve function,
the former still including, however, H–B grades I and II.
Regarding hearing preservation, 36% had serviceable hearing,
including 6 patients with G–R 2 and 2 patients with G–R 1;
one had decreased hearing function at 6 months after radio-
surgery (passing from G–R 2 to G–R 4). Facial numbness was
encountered in 18% immediately after surgery, showing im-
provement within the follow-up course; 9% experienced tem-
porary dysphagia and dysarthria. The mean time between sur-
gery and radiosurgery was 9.5 months. In this series, the ra-
diosurgery management was heterogeneous, with 9 cases un-
dergoing GKRS and 7 hypofractionated regimens [53].
Again, compared with those results, our series of 32 pa-
tients with large VS provides optimal results, with a normal
facial nerve function (H–B I) outcome in 100% of the cases,
and a high rate of hearing preservation (77.8% of the patients
in G–R 1 preoperatively remained at G–R 1, and 92% of the
patients with residual hearing G–R 1–3 preoperatively
remained in G–R 1–3 postoperatively).
Achieving the optimal residual tumor volume for radiosur-
gery after microsurgical resection is not always easy, especial-
ly when cochlear nerve function preservation is the goal. This
is exemplified in our series, where we found in 3 patients that
the residual volume was too large for safe GKRS and we
therefore decided on a second planned subtotal surgery. The
facial nerve outcome was identical after the second surgery
and GKRS (H–B I), but 1 patient lost hearing. However, the
benefit of a staged resection needs to be balanced with the
morbidity associated with a second hospitalization and crani-
otomy. If a single-stage excision can achieve the same out-
come, this situation remains preferable [22]. In our experi-
ence, the 3 patients who needed staged surgery clearly reflect
the learning curve of the technique that we have developed.
The inherent philosophy of combining surgery with radio-
surgery needs a good understanding of both the therapeutic
steps and its respective safety–efficacy evaluation. Although
the microsurgeon can avoid direct dissection between the tu-
mor capsule and the facial and cochlear nerves and improve
the functional outcome of resection with a Bnerve-centered^
tumor surgery approach, the GKRS surgeon needs to appreci-
ate that treatment planning may be more difficult because of
the modification of local conditions as a result of surgery, to
achieve a treatment plan that allows for the best functional
outcome, as for smaller tumors. Both the extent of the planned
microsurgical resection and the radiosurgical management,
including its timing, are key to the success of this approach.
There are 2 strategies for the subtotal resection of large VS.
One consists in a planned subtotal resection in which the neu-
rosurgeon focuses the technique on cranial nerve preservation
and on resecting only the amount of tumor that is needed to
render the residual tumor volume compatible with radiosur-
gery. This yields to the best functional outcome, as recently
reviewed by Iwai et al. [28] and reported in our series. Another
approach consists in performing a near-total extirpation,
aiming to leave only a small tumor remnant, usually at the
level of the internal acoustic porus, considering that it is the
location in which the facial nerve is particularly at risk for
injury and functional impairment. This approach, whose goal
is also a better functional outcome, has proven to be less
favorable. For example, in the recent publication by Jeltema
et al. [30], aimed at near total extirpation of large VS with
salvage radiosurgery only when the remnant is showing
growth, normal facial nerve function (H–B I) was achieved
in only 57.7% of the cases, whereas 32.7% of the patients had
mild (H–B II–III) facial function impairment after surgery, and
9.6% had severe (H–B IV–V) impairment; there was no men-
tioning of the hearing status. Thus, this later approach does not
represent a Breal^ planned subtotal extirpation, and functional
results might have been better if a larger residual tumor had
been left in place. The subsequent, and related, issue concerns
the timing of radiosurgery after subtotal resection of VS.
Although Jeltema et al. [30] are in favor of salvage radiosur-
gery only when the remnant is growing, arguing that it was
needed in only 13% of their series, we and others [28] believe
that in planned subtotal resection, when a larger piece of VS is
left in place, GKRS should take place in the months following
surgery, as part of a combined approach. We consider that the
residual tumor is at a high risk for further regrowth and we
prefer to perform GKRS when the residual VS has a volume
and anatomical relationship that is suitable for optimal radio-
surgery dosimetry planning and treatment.
Study limitations
There are several limitations of the present study. The first is
the short follow-up period following surgery and GKRS; there
is a need for further evaluation and re-confirmation of the
current clinical and neuroimaging results presented in this
study. Second, owing to the small sample size, the statistical
power is limited. Third, there was a relatively short interval
between the surgical resection and GKRS targeting, which
may not have offered enough time for good visualization of
the tumor and thus allow optimal GKRS targeting. Fourth,
there is an ongoing debate concerning the regrowth of the
residual tumor after surgery and the possible need for further
irradiation. In our center, the current strategy is to offer a
combined treatment to the patient from the very beginning,
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including both a planned subtotal surgery and further GKRS
on the residual tumor several months later.
Conclusion
The results of this series of large VS show that planned sub-
total resection followed by GKRS has an excellent clinical
outcomewith regard to facial nerve (100%H–B I) and cochle-
ar nerve (77.8%G–R 1; 92%G–R 1–3) function preservation.
Surgery for large VS has significantly changed from the total
excisions performed previously to a Bnerve-centered^ tumor
surgery approach. This shift in treatment paradigm will need
to be confirmed with long-term results following the GKRS.
As these long-term results emerge, this method of combining
subtotal surgery with GKRS in a planned manner warrants
strong consideration as the preferred option for patients with
large VS. Indeed, our results with planned subtotal resection
followed by GKRS in large VS compare favorably with the
results obtained with first-line GKRS in small- and medium-
sized VS, allowing to match similar expectations for patients
with larger VS needing surgical removal.
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